Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...